Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary CytomX Therapeutics and ImmunoGen, Inc. Announce Strategic Collaboration to Develop Probody-Drug Conjugates Against Cancer Targets
— Collaboration enables creation of PDCs using CytomX's Probody Platform and ImmunoGen's ADC technology — SOUTH SAN FRANCISCO & WALTHAM, Mass. --(BUSINESS WIRE)-- CytomX Therapeutics , the Probody™ therapeutics company, and ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops
View HTML
Toggle Summary Daniel Junius to Retire as President and CEO of ImmunoGen, Inc.
- Successor Expected to be Announced Shortly - WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN) a biotechnology company that develops targeted anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that Daniel Junius , age 63, has decided to
View HTML
Toggle Summary Debiopharm International SA Enters the Field of Antibody-Drug Conjugates Through Acquisition of Phase II Asset from ImmunoGen
Transaction adds innovative clinical-stage program to expanding Debiopharm portfolio and broadens its clinical development expertise Divestiture aligns with ImmunoGen's focus on strategic growth initiatives and generates near-term value LAUSANNE, Switzerland & WALTHAM, Mass.
View HTML
Toggle Summary First Clinical Data Presented with IMGN853, ImmunoGen, Inc.'s Potential New Therapy for Ovarian and Other Cancers
First clinical findings presented with ImmunoGen's folate receptor α (FRα)-targeting antibody-drug conjugate (ADC), IMGN853. Preliminary evidence of activity seen in dose-finding portion of trial. WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that
View HTML
Toggle Summary ImmunoGen and Merck Establish Collaboration for Clinical Evaluation of Mirvetuximab Soravtansine in Combination with Keytruda® (pembrolizumab) for the Treatment of Ovarian Cancer
− ImmunoGen's mirvetuximab soravtansine folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) to be assessed in combination with Merck's anti-PD-1 therapy − WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops novel anticancer
View HTML
Toggle Summary ImmunoGen and Sanofi Amend License Agreements
Amendments Grant Sanofi Exclusive, Fully-Paid Licenses to Selected Development Compounds ImmunoGen to Receive $30 Million License Fee WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer,
View HTML
Toggle Summary ImmunoGen Announces Accelerated Approval Pathway for Mirvetuximab Soravtansine in Ovarian Cancer
Top-Line Data from New Pivotal Single-Arm Trial, SORAYA, Expected in First Half of 2021 Confirmatory MIRASOL Trial for Mirvetuximab on Track to Start by Year-End Conference Call to be Held at 8:00 a.m. ET Today WALTHAM, Mass. --(BUSINESS WIRE)--Dec. 17, 2019-- ImmunoGen Inc.
View HTML
Toggle Summary ImmunoGen Announces Agreements to Exchange $76.4 Million of Its 4.50% Convertible Senior Notes Due 2021 for Common Stock
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (NASDAQ:IMGN) ("ImmunoGen" or the "Company") today announced that it has entered into privately negotiated exchange agreements with a limited number of holders of its 4.50% Convertible Senior Notes due 2021.
View HTML
Toggle Summary ImmunoGen Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 27, 2020-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the closing of its previously announced underwritten public offering of 24,523,750 shares of its common
View HTML
Toggle Summary ImmunoGen Announces Closing of Public Offering of Common Stock
WALTHAM, Mass. --(BUSINESS WIRE)--Jun. 11, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the closing of its previously announced underwritten public offering of 13,700,000 shares of its common
View HTML